-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Aerovate Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2021 to Q3 2025.
- Aerovate Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2025 was $2.23M.
- Aerovate Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was $3.64M, a 99.1% increase year-over-year.
- Aerovate Therapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was $5.02M, a 15.5% decline from 2023.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)